DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Dulaglutide
GLP-1 agonistFDA approvedRx required

Dulaglutide

Also known as: Trulicity · LY2189265
Brands: Trulicity

Long-acting GLP-1 receptor agonist approved for type 2 diabetes; IgG4 Fc fusion gives once-weekly dosing.

A
Grade A
Multiple human RCTs
Human studies25
PubMed citations27
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

GLP-1 analog fused to a modified human IgG4 Fc fragment. Resistant to DPP-4 cleavage; half-life ~5 days enables weekly subcutaneous dosing. Stimulates glucose-dependent insulin secretion and suppresses glucagon.

Evidence summary

25
Human studies
27
PubMed citations
25
Clinical trials
A
Evidence grade

AWARD clinical trial program (AWARD-1 through AWARD-11). REWIND trial demonstrated cardiovascular benefit in T2D patients.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

From the FDA label
Source
abdominal painacute kidney injuryastheniaconstipationdecreased appetitediabetic retinopathydiarrheadyspepsiaeructationfatiguegastroesophageal reflux diseasehypoglycemianauseapancreatitisrashtachycardiaurticariavomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for type 2 diabetes (Trulicity)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07537088Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled StudyNot Yet Recruiting · Phase 4 · T2DM · n=468NCT07027969Efficacy of Cardiometabolic Risk Factor Control Through Metabolic Surgery on Management and Severity of Atrial Fibrillation: METSAFE Randomized Clinical TrialNot Yet Recruiting · Phase 4 · Atrial Fibrillation · n=100NCT07313813A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes MellitusActive Not Recruiting · Phase 1 · Type 2 Diabetes Mellitus (T2DM) · n=20NCT05390892PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesRecruiting · Phase 4 · Type2Diabetes · n=6000NCT05478707Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesSuspended · Phase 2 · Diabetes Mellitus, Type 1 · n=47NCT06235086A Multicenter, Randomized, Open-label, Controlled Phase 3 Trial of TG103 Injection in Combination With Metformin in Subjects With Type 2 Diabetes MellitusCompleted · Phase 3 · Type 2 Diabetes Mellitus · n=632NCT06739122A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes MellitusRecruiting · Phase 3 · Type 2 Diabetes · n=55NCT06851962Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.Active Not Recruiting · Phase 4 · Diabetes Mellitus Type 2 · n=504NCT07417618Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.Active Not Recruiting · Type 2 Diabetes · n=60000NCT07417631Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.Active Not Recruiting · Type 2 Diabetes · n=30000NCT03498001Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingCompleted · N/A · Type II Diabetes · n=42NCT07370922Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaCompleted · Phase 2 · Transfusion Dependent Beta Thalassemia · n=80

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41407860Guo L, Zhang B et al. · Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature (2026)HumanPMID 40183678Billings LK, Winne L et al. · Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.Annals of internal medicine (2025)HumanPMID 41082229Derington CG, Sarwal A et al. · Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.JAMA network open (2025)HumanPMID 40172827West J, Li M et al. · Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.Neurology and therapy (2025)HumanPMID 39639536Aranäs C, Edvardsson CE et al. · The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats.Acta neuropsychiatrica (2025)PMID 41406444Nicholls SJ, Pavo I et al. · Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine (2025)HumanPMID 38449772Aoun L, Almardini S et al. · GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.Journal of clinical & translational endocrinology (2024)HumanPMID 38407177Urva S, Levine JA et al. · Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.Current medical research and opinion (2024)HumanPMID 39186787Hong B, Bea S et al. · Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.Annals of internal medicine (2024)HumanPMID 37821008Watanabe JH, Kwon J et al. · Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.Journal of the American Pharmacists Association : JAPhA (2024)HumanPMID 38651744Gao X, Di Y et al. · A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.Clinical and translational science (2024)HumanPMID 37369232Frias JP, Hsia S et al. · Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) (2023)HumanPMID 37286889Barrett A, Debackere N et al. · Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.Advances in therapy (2023)HumanPMID 37991022Probst L, Monnerat S et al. · Effects of dulaglutide on alcohol consumption during smoking cessation.JCI insight (2023)HumanPMID 36722623Takahashi Y, Nomoto H et al. · Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).Diabetes, obesity & metabolism (2023)HumanPMID 37231200García-Casares N, González-González G et al. · Effects of GLP-1 receptor agonists on neurological complications of diabetes.Reviews in endocrine & metabolic disorders (2023)HumanPMID 35658022Arslanian SA, Hannon T et al. · Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.The New England journal of medicine (2022)HumanPMID 32519795Urva S, Coskun T et al. · The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.Diabetes, obesity & metabolism (2021)HumanPMID 33236115Thomas MK, Nikooienejad A et al. · Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism (2021)HumanPMID 32564337MacIsaac RJ · Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)

Showing 20 of 27 papers. View all on PubMed →